Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 46

1.

The papilionaceous alkaloids; Baptisia minor, Lehm.

MARION L, COCKBURN WF.

J Am Chem Soc. 1948 Oct;70(10):3472-4. No abstract available.

PMID:
18891896
3.
4.

A double-blind study evaluating the long-term safety of varenicline for smoking cessation.

Williams KE, Reeves KR, Billing CB Jr, Pennington AM, Gong J.

Curr Med Res Opin. 2007 Apr;23(4):793-801.

PMID:
17407636
5.

The FDA approves new drug for smoking cessation.

[No authors listed]

FDA Consum. 2006 Jul-Aug;40(4):29.

6.

Cytisine for the treatment of nicotine addiction: from a molecule to therapeutic efficacy.

Tutka P, Zatoński W.

Pharmacol Rep. 2006 Nov-Dec;58(6):777-98. Review.

7.

CNS localization of neuronal nicotinic receptors.

Nashmi R, Lester HA.

J Mol Neurosci. 2006;30(1-2):181-4. Review.

PMID:
17192671
8.

Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid.

Rollema H, Chambers LK, Coe JW, Glowa J, Hurst RS, Lebel LA, Lu Y, Mansbach RS, Mather RJ, Rovetti CC, Sands SB, Schaeffer E, Schulz DW, Tingley FD 3rd, Williams KE.

Neuropharmacology. 2007 Mar;52(3):985-94. Epub 2006 Dec 8.

PMID:
17157884
9.

Effectiveness of smoking cessation therapies: a systematic review and meta-analysis.

Wu P, Wilson K, Dimoulas P, Mills EJ.

BMC Public Health. 2006 Dec 11;6:300. Review.

10.

Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation.

Oncken C, Gonzales D, Nides M, Rennard S, Watsky E, Billing CB, Anziano R, Reeves K.

Arch Intern Med. 2006 Aug 14-28;166(15):1571-7.

PMID:
16908789
11.
12.

Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial.

Tonstad S, Tønnesen P, Hajek P, Williams KE, Billing CB, Reeves KR; Varenicline Phase 3 Study Group.

JAMA. 2006 Jul 5;296(1):64-71.

PMID:
16820548
13.

Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.

Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, Billing CB, Gong J, Reeves KR; Varenicline Phase 3 Study Group.

JAMA. 2006 Jul 5;296(1):56-63. Erratum in: JAMA. 2006 Sep 20;296(11):1355.

PMID:
16820547
14.

Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.

Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, Watsky EJ, Gong J, Williams KE, Reeves KR; Varenicline Phase 3 Study Group.

JAMA. 2006 Jul 5;296(1):47-55.

PMID:
16820546
15.

Hierarchical control of dopamine neuron-firing patterns by nicotinic receptors.

Mameli-Engvall M, Evrard A, Pons S, Maskos U, Svensson TH, Changeux JP, Faure P.

Neuron. 2006 Jun 15;50(6):911-21.

16.

The neurobiological basis for partial agonist treatment of nicotine dependence: varenicline.

Foulds J.

Int J Clin Pract. 2006 May;60(5):571-6. Review.

PMID:
16700857
17.

Differential regulation of mesolimbic alpha 3/alpha 6 beta 2 and alpha 4 beta 2 nicotinic acetylcholine receptor sites and function after long-term oral nicotine to monkeys.

McCallum SE, Parameswaran N, Bordia T, Fan H, McIntosh JM, Quik M.

J Pharmacol Exp Ther. 2006 Jul;318(1):381-8. Epub 2006 Apr 18.

18.

ABT-089, a neuronal nicotinic receptor partial agonist, for the treatment of attention-deficit/hyperactivity disorder in adults: results of a pilot study.

Wilens TE, Verlinden MH, Adler LA, Wozniak PJ, West SA.

Biol Psychiatry. 2006 Jun 1;59(11):1065-70. Epub 2006 Feb 23.

PMID:
16499880
19.

Developments in pharmacotherapy for tobacco dependence: past, present and future.

Foulds J, Steinberg MB, Williams JM, Ziedonis DM.

Drug Alcohol Rev. 2006 Jan;25(1):59-71. Review.

PMID:
16492578
20.

Supplemental Content

Support Center